| Issue Date | Title | Author(s) | Type | М-cat. |
| 2022 | Immune checkpoint inhibitors-induced diabetes mellitus: a growing clinical presentation requiring our attention (✓) | Popovic, Djordje S   ; Koufakis, Theocharis; Kovacevic, Bojan; Rizzo, Manfredi; Papanas, Nikolaos | Article | |
| 2022 | Double Diabetes: A Growing Problem Requiring Solutions (✓) | Popovic, Djordje S ; Papanas, Nikolaos | Article | |
| 2022 | Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises? (✓) | Papachristou, Stella; Popovic, Djordje S ; Papanas, Nikolaos | Article | |
| 2022 | The Role of Fructose as a Cardiovascular Risk Factor: An Update (✓) | Busnatu, Stefan-Sebastian; Salmen, Teodor; Pana, Maria-Alexandra; Rizzo, Manfredi; Stallone, Tiziana; Papanas, Nikolaos; Popovic, Djordje S ; Tanasescu, Denisa; Serban, Dragos; Stoian, Anca Pantea | Article | |
| 2022 | Could cardiorenal benefits of sodium-glucose co-transporter 2 inhibitors be extended to type 1 diabetes mellitus? | Popovic, Djordje S ; Stoian, Anca Pantea; Papanas, Nikolaos | Contribution to periodical | |
| 2021 | New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications? (✓) | Popovic, Djordje S ; Rizzo, Manfredi; Stokic, Edita J ; Papanas, Nikolaos | Article | |
| 2021 | One-hour Post-load Plasma Glucose Cut-off Value for Diagnosing Diabetes: Do the New Data Bring us Closer to the Answer? | Popovic, Djordje S ; Papanas, Nikolaos | Contribution to periodical | |
| 2021 | Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review (✓) | Popovic, Djordje S ; Papanas, Nikolaos; Pantea-Stoian, Anca; Rizvi, Ali A; Janez, Andrej; Rizzo, Manfredi | Article | |
| 2021 | Beta-Catenin Signaling Pathway: Perhaps We Should Start Exploring it for Diabetic Foot Ulcer Healing? (✓) | Papanas, Nikolaos; Popovic, Djordje S | Article | |
| 2021 | The new dual gastric inhibitory peptide/glucagon-like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright? (✓) | Papachristou, Stella; Popovic, Djordje S ; Papanas, Nikolaos | Article | |
| 2021 | Clinical Benefit of Insulin Glargine 300 U/mL Among Patients with Type 2 Diabetes Mellitus Previously Uncontrolled on Basal or Premixed Insulin in Serbia: A Prospective, Observational, Single-Arm, Multicenter, Real-World Study (✓) | Velojic-Golubovic, Milena D ; Ciric, Vojislav M ; Dimitrijevic, Marija V; Kovic, Tijana; Mitic, Milica; Olujic, Biljana; Pevac, Natasa; Radenkovic, Sasa P ; Radojkovic, Danijela B ; Vukadinovic, Selena;
Popovic, Djordje S ; | Article | |
| 2020 | The predictive value of various visceral adiposity indicators in detecting the presence of impaired fasting glucose | Popovic, Djordje S ; Vukovic, Bojan; Mitrovic, Milena M ; Tomic-Naglic, Dragana D; Stokic, Edita J | Article | |
| 2020 | 1 h post-load plasma glucose: Should it be re-examined as a diagnostic criterion of diabetes? | Popovic, Djordje S ; Papanas, Nikolaos | Contribution to periodical | |
| 2020 | Beneficial renal effect of insulin glargine 300 U/ml initiation in type 2 diabetes mellitus patients previously treated with insulin | Popovic, Djordje S ; Lelik-Tubic, K | Article | |
Popović, Đorđe